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1.1 HYPERTENSION: AN OVERVIEW 
	
 
Cardiovascular changes furnish the fundamental process in the largest number 
of deaths after the 40th year. Each year cardiovascular disease (CVD) causes 3.9 
million deaths in Europe and over 1.8 million deaths in the European Union (EU). 
CVD accounts for 45% of all deaths in Europe and 37% of all deaths in the EU. 
CVD is the main cause of death in men in all but 12 countries of Europe and is the 
main cause of death in women in all but two countries 
(http://www.ehnheart.org/cvd-statistics.html), in fact hypertension generates over 
7 million early deaths per year and is responsible of 4.5% of the total diseases 
(Buford, 2016). Current data from the National Health and Nutrition Examination 
Surve show that 70% of older adults have hypertension, compared to only 32% for 








“Although hypertension is relatively easy to prevent, simple to diagnose, and 





Americans, and as such should rightly be called a neglected disease” said David 
W. Fleming, MD, chair of the committee that prepared the report (Buford, 2016). 
More than ninety percent of cases that do not have a recognizable cause are 
classified as essential or primary hypertension (Singh, Chapleau, Harwani, & 
Abboud, 2014) 
Over 60 years ago, Dr. Irvine Page suggested the Mosaic Theory of hypertension, 
which declares that different factors, including genetics, environment, adaptive, 
neural, mechanical and hormonal perturbations cooperate to raise blood pressure. 
Now it is known that the production of reactive oxygen species (ROS) and 
inflammation are two among the main common molecular and cellular events in 
various organs that inspired the Mosaic Theory. Neuronal firing in specific brain 
centers and sympathetic outflow are increased by these factors. Furthermore, they 













1.2 HYPERTENSION AND INFLAMMATION 
	
	
Low-grade inflammation performs a key role in hypertension and innate and 
adaptive immune system and seems to concur to hypertension progress and 
maintenance (Bomfim, Rodrigues, & Carneiro, 2017) 
There is a strong association between hypertension and immune system but the 
mechanism that stimulate immune system and inflammation are totally unknown. 
Cells from the innate immune system express pattern recognition receptors (PRR), 
which detect conserved pathogen-associated molecular patterns (PAMPs) and 
damage-associated molecular patterns (DAMPs) that induce innate effector signals 
to give endogenous signals such as inflammatory cytokines and chemokines, to 
warn the host about peril. Furthermore Antigen-presenting cells (APC) act as 
sentinels that are activated by PAMP and DAMPs to feel the presence of the 












The major effectors of the innate immune system are monocytes, macrophages, 
granulocytes, neutrophils and dendritic cells (DC) and tissue infiltrated by these 
cells are part of inflammatory response in distinct hypertension model. In 
particular, lysozyme M-positive monocytes have been involved in Angiotensin II 
(AngII)-induced hypertension and vascular dysfunction (Wenzel et al., 2011). 
Similarly, mice with functionally-deficient macrophages develop blunted 
hypertension and vascular remodeling in response to AngII or deoxycorticosterone 
acetate-salt (DOCA-salt) (De Ciuceis et al., 2005).  
Monocyte/macrophage function can be modulated by mineralocorticoid receptors 
(MR), whose (Rickard et al., 2009) deletion from macrophages protects against 
cardiac fibrosis and hypertension in response to DOCA-salt. Macrophages are also 
involved in salt-dependent volume and blood pressure, via a VEGF-C-dependent 
mechanism (Machnik et al., 2009). All these results have been obtained in animal 
models, but the innate system is as well important in human hypertension. In 
hypertensive patients, blood neutrophils are increased, and this increase has been 
suggested as a useful biomarker (Liu et al., 2015).  
Another immune cell population important for the development of hypertension 
are dendritic cells. Actually, some DAMPs, such as the γ-ketoaldehydes isoketals, 
are able to activate dendritic cells in hypertensive conditions, after being oxidized 
and phagocytized by these leukocytes (Kirabo et al., 2014; Wu et al., 2015).  
Moreover, dendritic cells can be stimulated by AngII, determining superoxide 
production and accumulation of isoketals (Harrison, 2016). When isoketals are 
scavenged, there is not activation of dendritic cells in the kidney. Consequently, 
dendritic cells fail to induce proliferation of T-cells, and blood pressure does not 
increase in response to AngII.  
Activation of innate immune responses is also associated by AngII induced 
hypertension. Infusion of AngII for 14 days increases tumor necrosis factor-
alpha (TNF-α) (Ahn et al., 2007) and increases TLR2 gene expression and DC 
number into the kidney. In fact, TLR4 upregulation seems to contribute to AngII 
induced hypertension (De Batista et al., 2014; Ding et al., 2010).   
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The innate and adaptive immune systems work in a very coordinated manner. The 
role of the adaptive immune system in hypertension has been progressively 
demonstrated, in the last decade. Therefore, the question whether both systems 
communicate during hypertension development has come to light. Various studies 
demonstrate that they play a key role in the development of adaptive immune 
responses in TLR	signaling pathways, upregulating co-stimulatory molecules of 
APCs (Brentano, Kyburz, Schorr, Gay, & Gay, 2005), important for the interaction 
with T-cells. These co-stimulatory molecules have been involved in the 
development of hypertension (Vinh et al., 2010). 
There are five different main subtypes of lymphocytes: CD4 T-cell, CD8 T-cell, 
B-cell, γδ T-cell and Natural Killer T (NK-T) cell. Evidence from experimental 
and clinical studies indicates that alterations in immune cell populations, such as 
activation of different lymphocyte subtypes, play an important role in the 
pathogenesis of hypertension (Idris-Khodja, Mian, Paradis, & Schiffrin, 2014; 




























The important role of lymphocytes in hypertension has started to be revealed fifty 
years ago. Researcher of University of Texas showed that transfer of lymphocytes 
from rats with renal damage induces hypertension in normotensive rats (Okuda & 
Grollman, 1967). 
Then in 1986 a research of University of Lyon demonstrated that neonatal 
thymectomy prevents the natural rise in systolic blood pressure in spontaneously 
hypertensive rats (Bataillard, Freiche, Vincent, Sassard, & Touraine, 1986). 
Hypertensive patients with rheumatoid arthritis or psoriasis, treated with a T-cell 
suppressing agent, have an important reduction of blood pressure, and these results 
was confirmed in animal models (Bravo, Quiroz, Ferrebuz, Vaziri, & Rodríguez-
Iturbe, 2007; Herrera, Ferrebuz, MacGregor, & Rodriguez-Iturbe, 2006; Muller et 
al., 2002). This was confirmed by Guzik et al. in 2007. In this study the researchers 
showed that T lymphocytes concur to the progression of hypertension by the study 
of RAG1 KO mouse, which lack T and B lymphocytes. This mouse model have 
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tick hypertension, aortic endothelial dysfunction, vascular remodeling and 
oxidative stress in response to AngII. (Guzik et al., 2007). This phenotype is re-
established by adoptive transfer of T-cells, but not B-cells, in response to AngII. 
Similar T-cells are shown their importance in other experimental models of 
hypertension (Mattson et al., 2013). 
Recently, researches of Duke University showed that, Scid mice without 
lymphocyte responses have a dampen hypertensive response to chronic AngII 
infusion, develop less cardiac hypertrophy and kidney injury. At the same time, 
Scid mice display upregulation of TNF-α, endothelial nitric oxide synthase 
(eNOS) and COX-2 in the kidney. The authors hypothesize that increased TNF-α 
expression in these animals might lead to dysregulation of macrophage function 
or upregulation of innate immune responses in the absence of adaptive immunity 















Angiogenic growth factors, besides inducing vessel growth and promoting 
inflammation, contribute to the adaptation of cardiac muscle to high blood 
pressure. For example, defects in cardiac vascular endothelial growth factor 
(VEGF) impair the adaptive remodeling in overloaded hearts, accelerating the 
transition to heart failure (Izumiya et al., 2006). The research group I am working 
with has explored a similar role for placental growth factor (PlGF), a protein 
belonging to a family of vascular endothelial growth factor (VEGF)-related 
angiogenic factors. They started from the consideration that PlGF increases in 
hypoxic/ischemic myocardium (Torry et al., 2009), and contributes to pathological 
angiogenesis, such as vascular regeneration under tissue ischemia (Autiero, 
Luttun, Tjwa, & Carmeliet, 2003). On the other hand, it has been demonstrated 
that the cytokine face of PlGF acts as a chemotactic agent for monocytes (Perelman 
et al., 2003; Pipp et al., 2003), which participate in the cardiac inflammatory 
response to pressure overload and support adaptive cardiac remodeling  (Endo et 
al., 2007).  Moreover, TNFα activation, one of the earliest inflammatory events in 
overloaded hearts (Wang et al., 2009), has been linked to PlGF to recruit 
myelomonocytic cells in inflamed tissues (Ding et al., 2010). In fact, TNFα needs 
to be shed from a membrane-bound form by TNFα–converting enzyme (TACE), 
and the main natural inhibitor of TACE is tissue inhibitor of metalloproteinases-3 
(TIMP-3), the most abundant TIMP expressed in cardiac tissue (Vanhoutte & 
Heymans, 2010). Interestingly, the lack of TIMP-3, producing excessive TNFα 
activation (Kassiri et al., 2005), promotes maladaptive cardiac remodeling, 
favoring the transition to heart failure. On the other hand, anti–TNFα therapy fails 
to be successful for heart failure treatment (Chung, Packer, Lo, Fasanmade, & 
Willerson, 2003; Mann et al., 2004), thus suggesting that, even if excessive 
inflammatory responses are detrimental, impaired inflammation also could be 
harmful, hampering an adequate tissue response to injury.  
Thus, PlGF was a good candidate to play a role in the complex cytoarchitectural 
response of the heart to hemodynamic overload. Thus, my research group 
demonstrated the pathophysiological role of PlGF in cardiac remodeling to 
pressure overload as both an angiogenic factor and a cytokine (Carnevale et al., 
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2011). They clarified that PlGF is increased in overloaded hearts and that, in this 
context, it influences mainly vessel dimensions. More important, we identified that 
PlGF finely tunes a balanced regulation of the TIMP-3/TACE axis and the 
consequent TNFα activation in response to TAC, thus ensuring an adequate 
















                                                                                                     
Chapter II: 










2.1 PLACENTAL GROWTH FACTOR 
	
	
Placental Growth Factor (PlGF) is a growth factor and a cytokine, involved in 
angiogenesis and inflammation. It is a member of the vascular endothelial growth 
factor family, and its 3D structure is very similar to that of VEGF-A, even if the 










Human PlGF gene has been mapped to chromosome 14q24, and is encoded by 
seven exons spanning an 800-kb-long DNA interval. As a protein, PlGF exists in 
four isoforms, generated by alternative splicing (PlGF-1, -2, -3 and -4), and acts 
as a dimeric protein held together by disulphide bonds (Nguyen et al., 2016). 
It was called Placental Growth Factor since it was first identified in placenta, in 
particular in trophoblastic giant cells associated with the parietal yolk sac at early 
stages of embryogenesis, suggesting a role to coordinate vascularization in the 
deciduum and placenta. PlGF has also been identified in lung, heart, thyroid, 
skeletal muscle, and adipose tissue under normal physiological conditions (Achen, 
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Gad, Stacker, & Wilks, 1997; De Falco, 2012; Persico, Vincenti, & DiPalma, 
1999; Viglietto et al., 1995; Voros et al., 2005). 
In cardiovascular pathophysiology, PlGF has a role in the adaptive response for 
cardiac remodeling during transverse aortic constriction (Carnevale et al., 2011) 
characterized by harmonized cardiomyocyte growth, angiogenesis and 
inflammation (De Falco, 2012; Frey & Olson, 2003; Hunter, Chien, & Chien, 
1999).   
This previous work, by the group I have worked with for my PhD, showed that 
genetic deletion of PlGF caused a dysregulation of cardiac remodeling negatively 
affecting muscle growth, mainly ascribable to a defective inflammatory response. 
At molecular level, this piece of research identified an impaired activity of TNF-α 
converting enzyme (TACE) due to a strong increase of its main natural inhibitor, 
tissue inhibitor of metalloproteinases (TIMP)-3 (De Falco, 2012; Vanhoutte & 
Heymans, 2010). TACE is essential to activate TNF-α, among the first cytokines 
released by inflammation in overloaded hearts (De Falco, 2012; Ding et al., 2010; 
Wang et al., 2009). PlGF, by regulating the TIMP-3/TACE axis, allows the 
establishment of an inflammatory response needed for adaptive cardiac 
remodeling (De Falco, 2012). 
The angiogenic role of PlGF is controversial. In some in vitro studies PlGF binding 
to VEGFR-1 failed to produce endothelial cells (EC) growth and angiogenesis, 
while other studies show that PlGF/VEGFR-1 signaling promotes EC viability and 
angiogenesis (Roy et al., 2005; Roy, Bhardwaj, & Ylä-Herttuala, 2006). In 
placenta and in PlGF-1 expressing tumors higher PlGF levels have been shown to 
inhibit EC growth (Ahmed, Dunk, Ahmad, & Khaliq, 2000; Roy et al., 2006). 
PlGF has direct eff ects on ECs, both by inducing its own signaling and by 
amplifying VEGF-driven angiogenesis (Autiero et al., 2003; Roy et al., 2006). 
PlGF binds the VEGFR-1 receptor, but not VEGFR-2 (Autiero et al., 2003; 
Carmeliet et al., 2001; De Falco, Gigante, & Persico, 2002; Otrock, Makarem, & 
Shamseddine, 2007; Roy et al., 2006). Moreover, the isoforms carrying heparin-
binding domain bind to neuropilin (De Falco et al., 2002; Nguyen et al., 2016). 
PlGF binding to VEGFR-1 has been observed to stimulate EC migration and 
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recruit cells involved in angiogenesis, such as monocyte macrophages, smooth 
muscle cells and pericytes ((De Falco, 2012; Nguyen et al., 2016). It has been 
hypothesized that PlGF binding to VEGFR-1 may stimulate angiogenesis also 
indirectly, by freeing up more VEGF-A to bind to VEGFR-2 (Autiero et al., 2003; 
Carmeliet et al., 2001; De Falco, 2012; Feeney et al., 2003; Fischer, Mazzone, 









In addition, leucocyte infiltration is connected with angiogenesis. VEGFR-1 
ligands are monocyte attractants and contribute to the recruitment of leucocytes. 
These recruited leucocytes provide an indirect (VEGF-independent) pathway of 
angiogenesis through the secretion of proangiogenic factors (Mantovani, Allavena, 










2.2 PLGF RECEPTORS 
	
	
2.2.1 Vascular Endothelial Growth Factor- Receptor 1 
	
As stated above, the canonical receptor of PlGF is VEGR-1 (Vascular Endothelial 
Growth Factor Receptor-1), also known as FLT-1, a tyrosine kinase receptor (TK 










Flt-1 consists of seven extracellular Ig-like domains, a transmembrane domain and 
an intracellular TK domain. Dimerization and phosphorylation of Flt-1 is induced 
by the binding of ligands. During development, VEGFR-1 is first expressed in 
angioblasts and in the endothelium and its expression decreases during later 
embryonic stages (Fong, Rossant, Gertsenstein, & Breitman, 1995; Peters, De 
Vries, & Williams, 1993). VEGFR-1 is expressed in osteoblasts, 
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monocytes/macrophages, placental trophoblasts, renal mesangial cells and also in 
some hematopoietic stem cells (Zachary, 2001). Then VEGFR-1 expression is up-
regulated by hypoxia via a pathway activated by hypoxia-inducible factor-1 (HIF-
1) (Gerber, Condorelli, Park, & Ferrara, 1997). In 1996 Barleon and his 
collaborators showed that VEGFR-1 participates in monocyte migration (Barleon 
et al., 1996). 
Selvaraj group has shown that PlGF binding to VEGFR-1 in monocytes results in 
activation of PI3 kinase/AKT and ERK-1/2 pathways, leading to chemotaxis and 
the induction of a series of inflammatory cytokines in sickle cell disease (Selvaraj 
et al., 2003). Hattori et al. have shown that PlGF promotes recruitment of VEGFR-
1(+) hematopoietic stem cells from a dormant to a proliferative bone marrow 
environment, favoring differentiation and reconstitution of hematopoiesis (Hattori 
et al., 2002). Furthermore, VEGFR-1-specific PlGF binding can promote collateral 
vessel growth and arteriogenic activity in myocardial and limb ischemia through 
the recruitment of bone marrow cells such as monocytes (Luttun et al., 2002; Pipp 
et al., 2003). 
In the end Flt-1 has a low tyrosine kinase activity, and deletion of its tyrosine 
kinase domain does not affect vascular development (Autiero et al., 2003; 
Hiratsuka, Minowa, Kuno, Noda, & Shibuya, 1998). In fact mouse embryos 
lacking Flt-1 generates angioblasts, although blood vessel assembly and tube 












2.2.2 Neuropilin- 1 
	
Neuropilin (Nrp), a 130-kDa to 140-kDa cell-surface glycoprotein, was first 
identified as a receptor for semaphorin/collapsins, a large family of secreted and 
transmembrane proteins, which are repulsive guidance signals in axonal and 
neuronal development (Fuh, Garcia, & de Vos, 2000; Miao & Klagsbrun, 2000). 
Later, it was found that Nrp-1 is able to bind VEGF-A, VEGF-B and PlGF. A 
similar receptor, Nrp-2, binds VEGF-A, VEGF-C and PlGF (Bagri & Tessier-
Lavigne, 2002).  
During embryonic development, Nrp-1 is expressed in the nervous, 
cardiovascular, and skeletal systems (Kitsukawa, Shimono, Kawakami, Kondoh, 
& Fujisawa, 1995). In adults, its expression is extended to ECs, tumor cells, lung, 
heart, liver, kidney, pancreas, osteoblasts, and bone marrow stromal cells (Soker, 
Takashima, Miao, Neufeld, & Klagsbrun, 1998; Tordjman et al., 1999). In humans, 
the gene coding for Nrp-1 is located on chromosome 10, while the gene coding for 
Nrp-2 is located on chromosome 2; both genes are composed of 17 exons 
(BIELENBERG, PETTAWAY, TAKASHIMA, & KLAGSBRUN, 2006; Michael 
Klagsbrun, Takashima, & Mamluk, 2002). 
Nrp-1 acts as a co-receptor enhancing VEGF-A–VEGFR-2 interactions, forming 
complexes with VEGFR-1 and augmenting tumor angiogenesis in vivo (M 
Klagsbrun & D’Amore, 1991). Overexpression of Nrp-1 in chimeric mice leads to 
excessive capillary and blood vessel formation and hemorrhages associated to 
cardiac malformations (Kitsukawa et al., 1995). In chick embryos, endothelial 
Nrp-1 expression is mainly restricted to arteries, whereas Nrp-2 is primarily 
expressed in veins (Herzog, Kalcheim, Kahane, Reshef, & Neufeld, 2001). It is 
thought that Nrp-1 is required for cardiovascular development because it regulates 
VEGF165 levels (Kawasaki et al., 1999). 
The role of Nrp-1 in the development of the vascular system has been 
demonstrated by gene-targeting studies; in fact, genetic deletion of Nrp-1 leads to 
embryonic lethality (Kawasaki et al., 1999). Similar to VEGFR-1, a soluble 
naturally occurring isoform of Nrp-1 acts as a natural antagonist. Soluble Nrp-1 
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inhibits VEGF165 binding to tumor cells and endothelium and inhibits VEGF165-
induced tyrosine phosphorylation of VEGFR-2 in ECs (Otrock et al., 2007). 
Nrp-1 is expressed in angiogenic vessels in animal models (Gelfand et al., 2014; 
Lanahan et al., 2013; Nguyen et al., 2016) and in humans (Cui et al., 2003; Nguyen 
et al., 2016).  The blockade of neuropilin-1 in neonatal mouse retinas inhibits 
vascular remodelling, and renders vessels more susceptible to treatment with anti-







The role of PlGF in hypertension is coherent with what I have already discussed 
about an interaction between hypertension and inflammation. My researcher group 
gave a contribution to clarify the importance of PlGF in the connection between 
hypertension and inflammation. In particular, we showed a splenic mechanism 
activated by PlGF, responsible for T cells co-stimulation via CD86 and T-cells 
egression and homing in target organs (Carnevale et al., 2014). 
In particular, we found that, in PlGF WT mice, chronic infusion of AngII induce 
inflammation and fibrosis, that were absent in PlGF null mice. Furthermore, the 
echocardiographic analysis after chronic AngII, showed a hypertrophic response 
in WT mice but not in PlGF deficient mice, which are protected from cardiac 
remodeling and renal damage.  
Subsequently, to extricate the molecular mechanism  
underlying the protection from hypertension showed that PlGF doesn’t have a 
direct effect on vascular tissue. 
Also PlGF deficient mice vessels and kidneys, after AngII infusion, were devoid 
of T-cells infiltration. This protection is clear yet in pre-hypertensive phase (pre-
HTN -3 days). 
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Furthermore, by the splenic transplantation, my laboratory group, demonstrate that 
splenectomized mice are protected from AngII–induced BP increase. 
Surprisingly, the transplantation of PlGF deficient spleen in WT background 
protected to raise BP after chronic infusion of AngII and protect to infiltration of 
T-cells in organ target.    
In order to track unambiguously the fate of T-cells from the spleen to the target 
organ during hypertension, my group studied CD45.2 mice that given CD45.1 
spleen by transplantation and then infused with AngII to induce hypertension.  
They observed increased numbers of donor (CD45.1) T cells in aorta and kidneys 
of Ang-II pre-HTN animals, demonstrating that the immune cells infiltrating target 
organs in hypertension are of splenic origin. 
PlGF is expressed in the marginal zone (MZ) of spleen; this zone is enriched in 
macrophages and dendritic cells acting as antigen presenting cells (APC) and 
activating T-cells. They found that PlGF is crucial to allow T-cells co-stimulation 
via CD86 and their egress for the deployment toward vasculature of target organs, 














































An area of emerging interest in mechanistic studies on arterial hypertension 
revealed a crucial role of adaptive immunity. On this regard, our group is dedicated 
to the exploration of new mechanisms underlying the interaction between immune 
system and hypertension. In particular, after identifying Placental Growth Factor 
(PlGF) as a crucial factor in the dynamics of T-cell activation during hypertension, 
we aimed here at exploring the molecular mechanisms at the basis of this signaling 
pathway. The main PlGF "canonical" receptor is VEGR1, known as Flt1, 
belonging to the same family as the better known VEGFR2, main receptor of 
VEGF. However, more recent data suggest the existence of an alternative PlGF 
signaling mechanism mediated by Neuropilin1 (NRP1), a transmembrane protein 
mainly known for regulating different aspects of vascular and neuronal 
development.  
Moreover, high expression of PlGF receptor neuropilin 1 (Nrp1) correlates with 
poor overall survival in patients. It was demonstrated that PlGF and Nrp1 are 
required for the growth and spread of medulloblastoma: PlGF/Nrp1 blockade 
results in direct antitumor effects in vivo, resulting in medulloblastoma regression, 
decreased metastasis and increased mouse survival (Snuderl et al., 2013). 
By the way, we have established the co-expression and activation in response to 
AngII of both receptors in the spleen, where PlGF is produced, we explored these 
two different pathways of intracellular signaling using two transgenic models: 
 
1) VEGFR1/Flt1-TK-/-, mice with a deletion in the intracellular tyrosine kinase 
domain of VEGFR1, unable to activate the intracellular signal upon interaction 
with its ligand PlGF.  
2) Nrp1flox; LysM-Cre transgenic mice for conditional deletion of NRP1 exon 2 
through the strategy of the Cre/LoxP system exclusively in the monocyte-
macrophage line, since we had previously identified this cell line as a target of 








VEGFR1 is the first receptor that we investigated to explore the role of PlGF. 
First of all, we found that VEGFR1 is expressed in the spleen, in basal condition. 
Then we evaluated the expression of VEGFR1 in the spleen after chronic infusion 
of AngII. We found that VEGFR1 is upregulated after chronic infusion of AngII. 
We evaluated its expression in the marginal zone (MZ) of the spleen, in a network 
of follicular dendritic cells, identified by the ERTR7 and CD169 antigens. This 
zone of the spleen is particularly enriched in macrophages and dendritic cells with 
a highly specialized phenotype (Mueller & Germain, 2009) acting as antigen-
presenting cells (APCs) and directly or indirectly activating T-cells. So far, it is 
unknown how hypertensive stimuli are able to condition and organize adaptive 
immune responses in the spleen. Classically this happens when, after antigen 
uptake, APCs undergo a maturation process characterized by an increased surface 
expression of major histocompatibility complex II (MHCII) and the B7 ligands, 
CD80 and CD86 (Song, Lei, Xiong, & Haque, 2008).  
Interestingly, it has been demonstrated that the AngII hypertensive challenge is 
able to increase the percentage of cells expressing CD86 in the splenic reservoir, 
while the number of cells expressing CD80 and MHCII remained unchanged (Vinh 
et al., 2010). However, how hypertensive stimuli could check the costimulation 
axis of immune system is unknown. 
To clarify the real role of VEGR1 as a receptor of PlGF in hypertension-immune 
system scenario, we infused chronic AngII in VEGFR1 TK-/- mice.  
The VEGFR1 TK-/- mice lacked the TK domain but had the ligand-binding domain 















They were basically healthy, and their angiogenesis was almost normal (Hiratsuka 
et al., 1998). In contrast Fong et al. showed that VEGFR1-/- mice die in the 
embryonic stage due to the overgrowth and disorganization of blood vessels, thus 

















When we infused VEGFR1 TK-/- mice with AngII for 28 days, by osmotic pumps, 
we observed that the AngII induced a similar hypertension in both VEGFR1 TK-/- 
























Thus we hypothesized that hypertension involved a different PLGF transduction 
signal. However, it must be said that we cannot completely exclude that VEGFR1 
was involved because we only inhibited phosphorylation signal but not the 
VEGFR1 receptor itself. 
In looking for another receptor or co-receptor that could be involved in the blood 














VEGFR1 TK +/+ AngII
VEGFR1 TK -/- AngII
AngII
VEGFR1 TK +/+ Vehicle











3.3 NRP1: A NEW CANDIDATE 
	
 
Neuropilin (formerly A5 or A5 protein; (S Takagi, Tsuji, Amagai, Takamatsu, & 
Fujisawa, 1987; Shin Takagi et al., 1995) is a type I membrane protein that is 
highly conserved among vertebrates, including Xenopus laevis, chicken (Shin 
Takagi et al., 1995), and mice (Kawakami, Kitsukawa, Takagi, & Fujisawa, 1996). 
Two expression cloning studies have shown that neuropilin is a semaphorin III/D-
binding protein and mediates semaphorin III/D-induced chemorepulsive signals to 
DRG neurons (He & Tessier-Lavigne, 1997; Kolodkin & Ginty, 1997).  
However, the roles of neuropilin, particularly in vivo, have not been defined. There 
are two neuropilins, Nrp1 and Nrp2, two membrane proteins that regulate many 
aspects of vascular and neural development. Originally they were identified as co-
receptors in immunity priming of response (Kitsukawa et al., 1997). However, 
neuropilin1 has been subsequently identified also as a receptor able to bind and 
respond to PlGF. Thus, we hypothesized that Nrp1 could be involved in the 
immunity response to PlGF leading to high blood pressure. 
First of all, we evaluated the expression of Nrp1 in the spleen. The staining shows 




























3.3.1 Cre-Lox Tissue-Specific Knockout 
 
So to explore with better clarity Nrp1 and its probable PlGF receptor function in 
this AngII-induced hypertension model we generated a transgenic mouse with 
deletion for Nrp1. 
Because the deletion of Nrp1 in germinal line is embryonically lethal, we 
generated a conditional knockout for Nrp1 using a mouse with a Cre recombinase 
under lysozyme M promoter. This Cre recombinase generates a conditional 
deletion of Nrp1 in monocyte-macrophage line when crossed with a mouse with 
Nrp1 gene flanked by LoxP sequences to allow the conditional cut of the sequence 



































                        
 




















We obtained in this way four useful genotypes LysMCre+ Nrp1fl/fl, LysMCre- Nrp1 




Mutant = ~700 bp 
Heterozygote = ~700 bp and ~350 bp 
Wild type = 350 bp	
Mutant = 398 bp  
Heterozygote = 183 bp and 398 bp 







3.3.2 Selective deletion of Nrp1 in macrophages  
 
First of all we tested the efficiency of Cre recombinase in deleting Nrp1 in the 
monocyte/macrophage line by testing Nrp1 presence in monocyte-macrophage 
starting from total splenocytes by flow cytometry.  
The FACS analysis shows that the signal isotype of Nrp1+ is suppressed in 



























































3.3.3 LysNrp1 fl/fl Cre+ mice were protected from hypertension 
 
Once validated our model, we infused AngII for 28 days by osmotic pumps in the 
experimental groups showed above.  
LysMCre- Nrp1fl/fl, LysMCre+ Nrp1wt/wt and LysMCre- Nrp1wt/wt mice respondend 
to the chronic infusion of AngII with an increase in blood pressure of about 30 
mmHg, consistent with our previous observation in WT mice. 
Nrp1+  
Monocytes 






In contrast, LysM Cre+ Nrp1fl/fl mice, with selective deletion of Nrp1 in 
monocytes-macrophages, were unable to increase blood pressure in response to 
AngII.  
These results strongly indicate that Nrp1 has a fundamental role in mediating the 
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NRP1fl/fl LysMCre+       AngII











3.3.4 Selective deletion of Neuropilin1 in macrophages inhibits 
egression of T cells from spleen upon AngII. 
 
Subsequently we analyzed the presence of immune cells in the white pulp (WP) 
area of the spleen, by evaluating staining for the CD3 antigen, marking 
lymphocytes, by immunohistochemistry, and by evaluating the signal of the CD4 
and CD8 antigens, marking monocytes/macrophages, in WP by flow cytometry.  
Surprisingly the CD3 cells in the area of splenic white pulp (WP) were increased 
in LyMCre+ Nrp1fl/fl with AngII as compared to and LyMCre- Nrp1fl/fl treated in the 
same way (Fig. 18A).  
Similarly, the flow cytometry analysis showed a reduction of 
monocytes/macrophages in the WP of AngII-treated and LyMCre-  Nrp1fl/fl, but 
not in LyMCre+  Nrp1fl/fl mice (Fig.18 B-C). 
Moreover, LyMCre- Nrp1fl/fl mice showed a reduced WP area after AngII infusion, 
suggesting egression of lymphocyte cells from this region. In contrast, Nrp1-
ablated mice lacked this response (Fig. 18A). 
Overall, these data suggest impaired T-cells activation and egression from splenic 
reservoir toward inflamed target tissues.   
These results indicate that the protection manifested by LyMCre+ Nrp1fl/fl in 
response to AngII is similar to the protection previously observed by the same 
























































Lymphocytes homing to target organs during hypertension has been shown to be 
a crucial step for both raise in BP and end organ damage (Guzik et al., 2007), 
suggesting that the hypertensive challenge involves innate and adaptive immune 
responses. 
In the spleen, the innate and adaptive immune cells are organized to allow rapid 
sensing of challenges and consequently, molecular interactions that lead to 





































3.3.5 Selective deletion of neuropilin1 in macrophages protects from T-
cells infiltration in kidneys upon AngII. 
	
	
Immunohistochemistry for CD8+ and CD4+ T-cells in kidney, showed that 
LyMCre+ Nrp1fl/fl mice were protected from infiltration of immune cells in target 





































































































4.1 CONCLUDING REMARKS  
 
 
The hypertension has a high incidence worldwide and it is one of the major risk 
factor for stroke, heart failure, kidney disease and other pathologies. 	
In addition, the percentage of people who have a poorly controlled hypertension is 
very high and steadily increasing. 
The focus of my PhD dissertation, a topic that has been arguing over the last few 
years, sees the immune system playing an important role in giving rise to high 
blood pressure. 
This thesis focuses on Placentar Growth Factor (PlGF) present in cardiovascular 
and immune system, which is known to be implicated in various pathologies, such 
as hypertension in pregnancy, the growth of blood vessels inside of tumors, in 
macular degeneration linked to age.  
A study published on Immunity in 2014 by the research group in which I worked 
on the thesis has shown that PlGF is one of the main players in mediating the 
relationship in the immune system and hypertension and it is an important factor 
in the activation of T lymphocytes within the spleen and their subsequent 
migration to the blood vessels and to the organs that are typically damaged by 
hypertension. From this important premise my thesis starts. 
We have set the goal of looking for the PlGF receptor involved in the interaction 
between immune system and arterial hypertension identified in the previous work. 
Our study focuses on the study of two possible PlGF receptors: the canonical 
receptor VEGFR1 and the non-canonical receptor Nrp1. Our results have led us to 
establish Nrp1 as possible receptor candidate. 
In mice with conditional deletion of Nrp1 in the macrophage-monocyte line there 
is a protection against hypertension such as that observed in the  
PlGF-/- model. We also observed, in this experimental group, a reduced egress of 
the T-cells from the spleen and a reduced lymphocyte infiltrate in the target organs 
of pressure-induced injury. 
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In conclusion I can summarize by saying that VEGFR1-TK signaling is not 
required for the role of PlGF in AngII-induced hypertension; the expression of 
Nrp1 is indispensable in macrophages to allow blood pressure increase in response 
to AngII.  
Moreover, the selective ablation of Nrp1 in monocytes-macrophages hampers T-



















































5.1.1 Animals  
	
All animal handling and experimental procedures were performed according 
to European Communities guidelines (EC Council Directive 2010/63) and the 
Italian legislation on animal experimentation (Decreto L.vo 26/2014). The 
protocol was approved by the Italian Ministry of Health (Permit number 58/2012-
B). Mice of 12–15 weeks were used in all experiments. B6.129 (SJL)-Nrp1 tm2Ddg 
/J mice (here indicated like Nrp1flox/flox ) were bought by The Jackson Laboratories 
(Stock Number 005247). Mice of 8 weeks B6.129P2-
Lyz2tm1(cre)Ifo/J,  B6.129(SJL)-Nrp1tm2Ddg/J and VEGFR1 tyrosine kinase knockout 
mice (VEGFR1 TK−/− mice; 8 weeks old) with a C57BL/6 hybrid background. All 
animals were provided with food and water ad libitum. According to our 
experience and current literature on the same experimental models (Carnevale & 
Lembo, 2012; Guzik et al., 2007; House, Potier, Bisaillon, Singer, & Trebak, 2008; 
Swirski et al., 2009; Vinh et al., 2010; Wenzel et al., 2011), the number of animals 
in each setting used was enough to determine whether there was a significant 
difference among groups, as tested by the software PS3. AngII (0.5 mg/kg/day) or 
vehicle (NaCl 0.9%) were delivered subcutaneously with osmotic mini-pumps 
(model 1007D, ALZET). At day 28, according to experimental design, mice were 








5.1.2 Generation of transgenic mouse Nrp1flox/flox LysMCre 
The Lyz2tm1(cre)Ifo/J  homozygous mice were backcrossed with C57BL6J mice (wt 
mice) to obtain mice bearing Cre recombinase in heterozygosis. 
The mice born from these couplings were coded (see section 5.1.2.1) and a PCR 
was performed on the tail piece to check its genotype. 
The primers used are: 
Forward primer 5’ - CCC AGA AAT GCC AGA TTA CG - 3’; 
Reverse primer 5’- TTA CAG TCG GCC AGG CTG AC - 3’; 
Common primer 5’ - CTT GGG CTG CCA GAA TTT CTC - 3’. 
The PCR conditions used were: 
 
 
The instrument used Proflex PCR system by Life Technologies.  
20ul of PCR final product was loaded on 1.5% agarose gel with addition of 1ul of 
ethidium bromide and using the EZ Load 100bp as molecular marker. The 
electrophoretic run was performed for 30’ minutes and 90 Voltage in a chamber 
for electrophoretic run. The products obtained were visualized using the Biorad 











The PCR conditions used were: 
 
	
We selected the heterozygous LysM mice for Cre recombinase and the  





                        




Afterwards we crossed LysMCre+ Nrp1 heterozygous mice with LysMCre- 
Nrp1 heterozygous mice. In this way, four useful genotypes (LysMCre+ 




5.1.2.1 Preparation of Genomic DNA from mouse tails. 
DirectPCR Lysis Reagent (Tail): Cat # 101-T, 102-T 1. For 0.5 cm tail, add 200–
300 µl DirectPCR Lysis Reagent (Tail) containing freshly prepared 0.2-0.4 mg/ml 
Proteinase K (Sigma, cat # p6556, not included). Proteinase K is stable in 
DirectPCR reagents for ~24 hrs. If a small number of tails are processed, and 
700bp Mutant 
350bp WT 
Mutant = ~700 bp 
Heterozygote = ~700 bp and ~350 bp 
Wild type = 350 bp	
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therefore it is difficult to weigh Proteinase K powder, use genomic PCR-quality 
Proteinase K solution (Viagen, cat #501-PK) at 0.5-1.0 mg/ml (25-50 µl Proteinase 
K solution per 1 ml DirectPCR reagent). See Table 1 for starting conditions. 
NOTE: Although 200 µl DirectPCR is usually sufficient for complete lysis of 0.5 
cm tail, application of 250-300 µl yields more reproducible results because of 
better mixing efficiency. Compare several different volumes of DirectPCR 
reagents for best performance. If tails are not mixed well with solutions, use 0.75 
ml tubes. 2. Rotate the tubes in rotating hybridization oven at 55°C for 5-6 hrs or 
until no tissue clumps are observed. If necessary, rotation can be allowed overnight 
without loss of efficacy. Complete lysis is important. Since some tails may not be 
in contact with solutions, re-position once the tails by shaking the bottles 
containing tubes, preferentially after 2-3 hrs.  
NOTE: Rotating hybridization oven performs better than rocking plate. Use 0.75 
cm tubes for less than 200 µl of DirectPCR Reagent. DNA fragmentation by 
prolonged rotation will not influence significantly PCR performance. Use roughly 
proportional volume of DirectPCR Lysis Reagent for different sized samples. 3. 
Incubate crude lysates at 85°C for 45 min by floating the whole rack (containing 
tubes) on a water bath. (Optional) Precipitate hairs by centrifuging for 10 sec 
before step 4. Crude lysates may be stored at -20°C for 1 year (or at 4°C for 1 
week) without losing efficacy. 4. Use 0.5-1.0 µl of lysate for 50 µl PCR reaction. 
Eppendorf Hotmaster Taq Polymerase (cat# 954-14-5018), Sigma JumpStart Taq 
DNA Polymerase (cat# D9307), or Qiagen HotStar Taq DNA polymerase (cat# 
203203) is recommended for PCR. Rescue of DNA: DNA in crude lysates can be 
rescued for further analysis. Add NaCl to a final concentration of 250 mM, and 
then add 0.7 volume of isopropanol. DNA will form precipitates. Centrifuge at 4°C 
for 2 min, discard supernatant, wash DNA with 1 ml 70% EtOH, and dissolve 
DNA in 50 µl 10 mM Tris-HCl (8.0). Use 1 µl for PCR. Table 1. Suggested starting 
lysis conditions for mouse tails. Tails (cm) DirectPCR (µl) Dilution (fold) Lysates 
(µl) / 50 µl PCR rxn. 0.2-0.3 150-200 2 1.0-2.0 0.4 150-250 1 0.5-1.0 0.5 200-300 
1 0.5-1.0 Related Products Products Description Cat # Price (US $) DirectPCR-
Tail 500 mouse tails (100 ml) 102-T 139 DirectPCR-Ear 500 mouse ears (50 ml) 
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402-E 139 DirectPCR-Yolk sac Yolk sac (100 ml) 202-Y 139 DirectPCR-Cell 
Cultured cell (100 ml) 302-C 139 Proteinase K Solution All types of tissues (100 
mg) 501-PK 99. 
Important Technical Tips 1. Complete lysis. Big tissue clumps should not be 
observed after digestion. It is recommended to vigorously shake the bottle 
(containing microfuge tubes) for 2-3 sec anytime, once or twice, after tissues begin 
to partially dissolve. This will physically disperse partially digested tissues and 
reposition microfuge tube, in which tails are separated from lysis reagents, thereby 
facilitating overall lysis efficiency, 2. Proteinase K inactivation. Inactivation of 
proteinase K by incubating samples at 85C-86C for 45-50 min is critical to protect 
Taq polymerase from proteinase K. 3. Taq polymerase. We have tested many types 
of commercially available Taq polymerases. The listed enzymes are recommended 
for optimal results. 4. Tissue size. The size of tails should be 0.5 cm or slightly 
smaller. Use a minimal volume (0.5-1 µl for 50 µl PCR reaction) of crude lysates 
for PCR amplification. Too much DirectPCR reagents inhibit PCR efficiency. 5. 
Small tubes and evaporation. To minimize evaporation, use a 0.75 ml tube when 
the reagent volume is less than 100 µl. 6. Small samples and dilution. If the 
required DirectPCR reagent volume is less than 50 µl, dilute the reagent by up to 
2-fold with water, while maintaining the same concentration of proteinase K. If 
the DirectPCR reagent is '2- fold' diluted, apply '2-fold' more crude lysates for PCR 
reaction. 7. PCR machine. PCR machines are occasionally a source of technical 
problems. 
 
5.1.3 Blood-Pressure Measurements 
	
Noninvasive blood pressure measurement was performed by tail-cuff 
plethysmography (BP-2000 Series II, Visitech Systems) in conscious mice daily 
for 2 hours (10 am–12 pm). Operators were blinded to the experimental group 




5.1.4 Isolation and Preparation of Single Cell Suspensions from Spleen, 
Kidney and Aorta 
	
Mice were anesthetized with ketamine/xylazine and spleen was isolated. Then, 
mice were exsanguinated and both kidneys and aorta were collected. Spleen was 
mechanically disrupted and then passed through a 40 µm sterile filter (Falcon, BD) 
and centrifuged at 300× g for 10 min. After a treatment with Lysing Buffer (BD), 
the pellet was resuspended in PBS. Total splenic leukocytes were stained and 
analyzed using flow cytometry or used to isolate and enrich 
monocytes/macrophages by negative selection, using a commercially available 
monocyte enrichment kit (EasySep Kit and Purple EasySep Magnet, Stemcell 
Tech). Kidney cell suspension was obtained disrupting mechanically two 
decapsulated kidneys, and then passed through a 70 µm sterile filter (Falcon, BD). 
The resulted cell suspension was centrifuged at 300×g for 10 min. To isolate 
lymphocytes from cell suspension, the pellet was then suspended in 36% Percoll 
(Sigma), gently overlaid onto 72% Percoll, and centrifuged at 1,000× g for 30 min 
at RT. Aorta cell suspension was obtained disrupting mechanically the tissue and 
digesting the suspension in Digestion Cocktail, was then passed through a 70 µm 
sterile filter (Falcon, BD), and centrifuged at 300× g for 5 min to pellet the cells. 
Before proceeding with stainings for flow-cytometric analyses, lymphocytes from 
kidney and aorta total cells were enriched with Mouse T Lymphocyte Enrichment 
Set-DM (BD IMag). Samples were resuspended in PBS and then the number of 
the cells was assessed using trypan blue and an automated counter (Countess, Life 
Technologies). 
 
5.1.5 Flow Cytometry Analysis 
	
Splenic leukocytes (1 × 106), enriched monocytes (2 × 105), total kidney, and 
aorta lymphocytes were preincubated with anti-CD16/32 Fc receptor and then 
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incubated with various combinations of mAbs, washed with PBS, centrifuged at 
300× g for 5 min at 4°C, and resuspended in FACS buffer. Immunofluorescence 
staining was analyzed using a C6 Accuri Flow Cytometer and BD FACSCanto 
(BD Biosciences). The data were analyzed using FlowJo Software. 
 
5.1.5.1 Antibodies 
The fluorochrome-conjugated mAbs to mouse antigens used for flow cytometry 
analysis were as follows: anti-CD16/CD32 (2.4G2), PE anti-CD86 (GL1), PE 
Isotype control Rat IgG2a, APC anti-CD11b (M1/70), PerCP-Cy5.5 anti-CD8a 
(53-6.7), FITC anti-CD8a (53-6.7), APC anti-CD3e (145-2C11), PerCP anti-CD45 
(30-F11), FITC anti-CD4 (RM4-5), PE anti-CD4(RM4-5), APC anti-CD69 
(H1.2F3), APC-Cy7 anti-CD45 (30-F11), FITC anti-F4/80 (FA-11) (AbD 
Serotec), and PerCP-Cy5.5 anti-CD68 (FA-11) (BioLegend), APC anti-
Neuropilin-1 (R&D). 
 
5.1.6 Histological Analysis, Immunohistochemistry, and 
Immunofluorescence 
	
Sections of kidney were deparaffinized, rehydrated, and then underwent antigen 
retrieval. Slides were processed for immunohistochemistry with the following 
primary antibodies: anti-CD8 and anti-CD4 (1:50; BD PharMingen). Appropriate 
biotinylated secondary antibodies (1:200; Vector) were used for successive 
processing with DAB (Vector). Hematoxylin (Sigma) was used as counterstaining. 
The number of CD8 and CD8-positive cells per mm2 was determined using the 
Image J software Cell Counter plugin analysis tool. 
For immunofluorescence analysis, 25 µm sections from spleen were postfixed with 
4% paraformaldehyde for 15 min and processed for staining with the following 
primary antibodies: rabbit anti-PlGF (Abcam) 1:250, rabbit-anti CD86 (Novus 
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Biologicals) 1:100, rat anti-mouse CD68 (AbD Serotec) 1:200, rat anti mouse 
CD169 (AbD Serotec) 1:100, Sheep-anti Tyrosine Hydroxylase (Millipore) 1:800, 
rat anti-mouse CD45R (B220, BD PharMingen) 1:50, anti-hamster CD3 (BD 
PharMingen) 1:50, rabbit anti VEGFR1 (R&D) 1:50, rabbit anti Nrp1 (R&D) 1:50 
and rat anti-ER-TR7 (Acris) 1:200. Sections were then incubated with the 
respective secondary antibodies conjugated to Alexa Fluor 488, Alexa Fluor 647 
or Cy3. Slides were then coverslipped with DAPI containing medium (Vector).  
 
5.1.7 Confocal Microscopy Analysis 
	
All coverslipped mounted tissue sections were scanned using a Zeiss 780 confocal 
laser scanning microscope with a Zeiss ECPLAN-NEOFLUAR 10x/0.30 M27, 
ECPLAN-NEOFLUAR 20x/0.50 M27, ECPLAN-NEOFLUAR 40×/1.30 M27 oil 
immersion objective or PLAN-APOCHROMAT 63×/1.4 oil DIC oil immersion 
objective (Carl Zeiss Microimaging Inc.). We used a 405 Diode laser to excite 
DAPI, a 488 nm argon laser to excite Alexa Fluor 488, and a 543 HeNe laser to 
excite Cy3. Pseudocoloring was performed using ZEN software (Carl Zeiss 
Microimaging) 
 
5.1.8 Bright-field Microscopy Analysis 
	
All images were captured using a DMI3000B Leica optical microscope provided 
of Leica cameras (Leica Microsystems) and processed with the Leica Application 





5.1.9 Statistical Analysis 
	
All the experiments were replicated within the laboratory. Sample size was pre-
estimated from the previously published research and from pilot experiments 
performed in the laboratory. Data are presented as mean±s.e.m. Data distribution 
was assessed with the Shapiro–Wilk normality test and D'Agostino Pearson test, 
and assumption of homogeneity of variance was tested using Levene's test of 
equality of variances. For amplitude gain analysis, unequal variance between 
groups was observed in a minority of cases, and a Welch correction was performed 
for all comparisons. Statistical significance was assessed with the appropriate test 
according to each experimental design, as detailed in figure legends. After 
confirming that all data had normal distributions, we applied Student t-test for 
either independent samples or paired samples, according to the experimental 
design and as specified in the figure legends. Multiple group analysis was 
performed with two-way ANOVA followed by Bonferroni's post hoc. Analysis for 
repeated measures was applied when required by the experimental setting. P<0.05 
was considered significant. Statistical analyses were performed with SPSS 23.0 
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